Empowering Research on Epilepsy Surgery Outcomes

Adam S. Dickey[1*], Robert T. Krafty[2], and Nigel P. Pedersen[1,3, 4]

[1] Division of Epilepsy, Department of Neurology, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA.

[2] Department of Biostatistics and Bioinformatics, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA.

[3] Department of Biomedical Engineering, Emory University and the Georgia Institute of Technology, Atlanta, GA, USA.

[4] College of Medicine and Public Health, Flinders University, GPO Box 2100 Adelaide SA 5001, Australia.

(*) Author to whom correspondence should be addressed:

Email: adam.s.dickey@emory.edu

Adam Dickey, MD, PhD

Woodruff Memorial Research Building, Room 6209

101 Woodruff Circle

Atlanta, GA, 30322

Phone: (404) 778-3444 Fax: 404-251-2639

Text pages: 19 Body word count: 1785

References: 18 Figures: 1 Tables: 1 Appendix: 1

Key words: Epilepsy surgery, Engel outcome, Seizure freedom, Statistical power

SHORT SUMMARY

We performed a systematic review to determine the median statistical power of studies of epilepsy surgery outcomes, focused on stereoelectroencephalography. We extracted patient count data for comparisons of outcomes between two groups. We defined a clinically meaningful difference as the prognostic value of a normal versus abnormal MRI. Based on 69 studies, the median sample size was 38 patients, and the median statistical power was 24%. Underpowered studies will overestimate the size of true effects and are more likely to report false positive results. We discuss how statistical power, and thus reproducibility and reliability of results, can be improved.

ABSTRACT

Low statistical power is a recognized problem in many fields. We performed a systematic review to determine the median statistical power of studies of epilepsy surgery outcomes. We performed a PubMed search for studies reporting epilepsy surgery outcomes for the years 1980-2020, focusing on studies using stereoelectroencephalography (SEEG). We extracted patient count data for comparisons of surgical outcome between two groups, based on a reported prognostic factor. We defined a clinically meaningful difference as the difference in seizure freedom for MRI positive (66.9%) versus negative (45.5%) from the largest study found. Based on 69 studies of surgery outcomes in patients undergoing SEEG, the median sample size was 38 patients, and the median statistical power was 24%. This implies at least a 17% chance a study with a significant result is false, assuming 1:1 pre-test odds. Results from simulation studies suggest that, if a typical SEEG study finds a significant effect, then the median observed effect size will be more than double the true effect size. We conclude that studies of epilepsy surgery outcomes using SEEG are often statistically underpowered, which limits the reproducibility and reliability of the literature. We discuss how statistical power could be improved.

Key words: Epilepsy surgery, Engel outcome, Seizure freedom, Statistical power

1 INTRODUCTION

Low statistical power is a recognized problem in many fields[1, 2], which means true effects will be missed, the chance a study with a significant result is false will be inflated[3], and discovered true effects will be over-estimated[4]. In neuroscience the typical power to detect a true effect was estimated at 20%[2]. We recently highlighted the issue of low power in a single study of laser surgery[5], but we suspected that low power was pervasive in studies of epilepsy surgery outcomes. We performed a systematic review to acquire a representative sample of papers reporting epilepsy surgery outcomes and determine the power of a typical study. We focus on stereoelectroencephalography (SEEG) to keep the review tractable, and because the recent adoption of this technique in the United States may lead to smaller number of patients and thus lower power.

A major challenge in any power analysis is determine the "clinical meaningful" effect size. This can be defined as how large of an effect we expect actually exists and that we want to be able to detect[1.]. The largest study in the SEEG literature we know of is from the Milan group, which reported outcomes of freedom from disabling seizures following surgery in 470 patients[6]. We use this large cohort to estimate a clinical meaningful effect size as the (statistically significant) prognostic value of an abnormal MRI: 66.9% (204/305) of patients with an abnormal MRI were seizure-free, compared to 45.5% (75/165) patients with a normal MRI (odds ratio 2.4, 95% CI 1.6-3.5). The presence of a lesion on MRI is not the only relevant prognostic factor but is commonly reported in the literature.

In our meta-analysis, we extracted the number of patients who were divided into two groups (such as MRI positive or negative) and computed the power of that study to predict a difference in seizure freedom of 66.9% versus 45.5%. We review options for computing power. We discuss the issues raised by underpowered studies and highlight options for improving power.

53

54 **2 METHODS**

55 **2.1 Literature Search**

56 We performed a PubMed search with the terms "((SEEG) OR (stereoelectroencephalography)) AND
57 (epilepsy) AND (surgery outcome)" for the year of publication from 1980 to 2020, last performed
58 March 2, 2021. One of us (ASD) reviewed each abstract, and then examined the full manuscript
59 when the abstract described a comparison of surgery outcome between two groups. Inclusion
60 criteria were 1) studies of patients undergoing SEEG that 2) report a comparison of surgical outcome
61 (good or bad) based on a prognostic factor. Exclusion criteria included reviews, small case series, or
62 mixed populations of SEEG and subdural grids. Raw patient counts were extracted for the
63 comparison most emphasized in the abstract. If raw patient counts were not reported as a two-by-
64 two table, we inferred the patient counts from information given in the text. Patient counts for each
65 included study are reported in the supplement (Appendix S1).

66

67 **2.2 Calculation of power**

68 We estimated the power of the Chi-square test for a difference in proportions using three methods.
69 First, we simulated binomial count data for each group using our predefined plausible effect size[6]
70 (66.9% vs. 44.5%). We simulated 10,000 repetitions and report the power as the percentage of
71 repetitions where a Chi-square test reported a p-value ≤ 0.05. We did this for each study using the
72 reported number of patients in each group. This software analysis was done in MATLAB (version
73 R2016b, Mathworks, Natick, MA) using the function **chisquarecont,** available on the MATLAB
74 Central File Exchange[7].

Second, we estimated the statistical power of the Chi-square test by approximation[8] (Equation 1) using the Gaussian cumulative density function (Φ) applied to a critical value, which is a function of the sample size (*n1* and *n2*) and percent seizure free (*p1* and *p2*)of each group, and the Z-score $z_{\alpha/2}$ (1.96 if $\alpha = 0.05$).

$$\Phi\left(\frac{|p_1 - p_2|}{\sqrt{p_1(1-p_1)/n_1 + p_2(1-p_2)/n_2}} - z_{\alpha/2}\right) \qquad \text{(Equation 1)}$$

Finally, we used the R package "Exact" and the function **power.exact.test** using method "pearson chisq" (R version 4.1.1, www.r-project.org) to compute power. Traditionally, Fisher's exact test is recommended if there is an expected cell count is less than 5, but is this is known to have lower power relative to a Chi-square test (and the equivalent Z-test) for many trial models[9]. For simplicity, we only consider Chi-square test, since if anything this will overestimate power relative to a mixture of Chi-square and Fisher's exact tests.

2.3 Chance a study with a significant result is false

A p-value is the probability of obtaining a test statistic from an independent study as or more extreme than the statistic from the observed study, assuming the null hypothesis is true[10]. That is, the p-value is a probability based on observed data given the null hypothesis. The p-value does not measure the probability that the data were produced by chance alone, or the probability the null hypothesis is true[11], which is a probability of the null hypothesis given the data. Bayes' Rule can be used to convert the probability of data given the null into the probability of the null given data. This requires the pre-study odds that the null hypothesis is true and, crucially, the statistical power. The positive predictive value (PPV) is given by the equation below, where (1-*Beta*) is the power, *Beta* is the Type II error, *Alpha* is the Type I error, and *R* is the pre-test study odds[2] (Equation 1)

$$PPV = ([1\text{-}Beta] \times R)/([1\text{-}Beta] \times R + Alpha) \quad \text{(Equation 1)}$$

We assume the pre-test odds *R* are 1:1, meaning the pre-test probability of the alternative hypothesis being true is 50%. This is the most optimistic plausible scenario. If the pre-test probability of the alternative is less than 50%, the PPV will be even lower[3]. The chance a study with a significant result is false is one minus the PPV (Equation 2).

$$\text{Prob(+Study is False)} = 1\text{-PPV} = Alpha/([1\text{-}Beta] \times R + Alpha) \quad \text{(Equation 2)}$$

2.4 Over-estimation of effect size

It is known that if a study is underpowered, then the an observed effect size will on average overestimate the true effect size if it is found to be statistically significant[4]. We define a "typical" SEEG study has having the median sample size with the median allocation ration across all included studies. Using the simulation paradigm described above, we quantify the over-estimation of a typical study by computing the median odds-ratio of runs with a Chi-square p-value <0.05, divided by the assumed odds ratio of 2.4.

3 RESULTS

We reviewed 119 manuscripts in detail, from the 268 abstracts returned by our search terms (and one added from citations). 69 studies met inclusion criteria, meaning they reported a comparison of good versus poor surgical outcome based on some prognostic factor in patients undergoing SEEG.

The median sample size was 38 patients (range 8-470). We estimated power using our assumed effect size of 66.9% vs. 45.5% seizure freedom between two groups. The median power using a chi-square test was 24% (range 7-99%) using the exact calculation using R or the simulation-based approach. The power was 22% using the Gaussian approximation, which slightly under-estimated the true power (Figure 1A). A power of 24% corresponds to a 17% (0.05/[0.24+0.05]) chance that a study with a significant result (at $p<0.05$) is false (Figure 1B).

The median allocation percentage was 63% of the patients in the positive group (roughly a 2:1 ratio). We therefore define a "typical" SEEG study as having median sample size (38) with the median allocation percentage (63%), which rounds to 24 patients in the positive group and 14 in the negative group. Based on simulations, the median odds ratio that was significant at $p<0.05$ was 5.4, which is more than double the assumed true odds ratio of 2.4 (Figure 1C). Thus, when a typical SEEG study finds a significant effect, its magnitude will be over-estimated.

Though clinical trials are often designed to achieve 80% statistical power, only 3% (2/69) of the surveyed studies had greater than 80% power to detect our assumed effect size. We highlight the seven studies which had more than 50% power to detect our assumed effect size (Table 1).

4 DISCUSSION

Based on a representative sample of 69 studies of epilepsy surgery outcomes in SEEG, we estimate that the median study has only 24% power to detect a clinically meaningful effect. Though we focused on SEEG, we expect low power is common in studies of epilepsy surgery. An underpowered study (by definition) has a low chance to detect a true effect when present. However, some studies incorrectly interpret absence of evidence as evidence of absence. If an underpowered study finds no statistical difference in seizure freedom between an MRI positive and MRI negative

group, then it is incorrect to conclude that MRI could not at least partially predict seizure freedom. If the study power is less than 50%, a negative result is expected even if the effect is real.

Another statistical fallacy is treating a result significant at $p<0.05$ as only having a 5% chance of being false[11]. The median SEEG study with 24% power has at least a 17% chance of being false, based on power considerations alone. Moreover, if an underpowered study finds a significant effect, it will over-estimate the effect size. Such limitations of low power are rarely discussed in epilepsy literature.

The biggest limitation of this study is our reliance on a single study of MRI positive vs. negative to determine the clinically meaningful effect size. There are countless possible prognostic factors, which may have different true effect sizes, which will be need quantified in future (ideally well-powered) studies. Our recommendation is that authors perform their own formal statistical power analysis, with an explicit definition of the clinically meaningful effect size. If the study is underpowered, that should be discussed in the interpretation of the results.

The most obvious (and most difficult) way to increase power is to include more subjects. This can be done by combining data across institutions, as done by one study highlighted here[12]. A less obvious way to increase power is to expand statistical analysis beyond the comparison of two-by-two tables of binary predictors and surgical outcomes. For example, we have shown that using ordinal regression using the full ordinal Engel surgical outcomes increases power relative to traditional binary logistic regression[13]. A similar increase in power should be possible by using continuous or ordinal predictors, rather than binary predictors.

5 CONCLUSION

Studies of epilepsy surgery outcomes in SEEG are systematically underpowered. Future studies should perform formal power analyses, and low power should be addressed by increasing the sample size and/or by statistical analysis which avoids unnecessary dichotomization. We call for increased statistical rigor in studies of surgery outcomes, as well as greater collaboration within the epilepsy community, with the goal of providing accurate and precise information to guide treatment for our patients with epilepsy.

FUNDING AND ACKNOWLEDGEMENTS

N.P.P. is supported by the Woodruff Foundation, CURE Epilepsy, and NIH grants K08 NS105929, R01 NS088748, and R21 NS122011. A.S.D. is supported by the National Center for Advancing Translational Sciences of the NIH under award number UL1 TR002378 and KL2 TR002381. R.T.K. is supported by R01 GM113243. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. MATLAB and R code which can be used to reproduce the analyses and figures described here will be posted at https://github.com/adamsdickey.

AUTHORSHIP STATEMENTS

A.S.D and N.P.P. contributed to the conception and design of the study. A.S.D, R.T.K and N.P.P contributed to the drafting of the text. A.S.D. performed the statistical analysis and prepared the figures and tables

DISCLOSURE OF CONFLICTS OF INTEREST

N.P.P. has served as a paid consultant for DIXI Medical USA, who manufactures products used in the workup for epilepsy surgery. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. A.S.D and R.T.K. have no conflicts of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines

FIGURES


A
100
80
60
40
20
0
% POWER
Well-powered study
Median study
0
50
100
150
200
SAMPLE SIZE (2:1 allocation)
B
100
80
60
40
20
0
% FALSE +Studies
Median study
Well-powered study
0
20
40
60
80
100
% POWER
C
40
30
20
10
0
%
True Odds Ratio
P>0.05
P≤0.05
Median Sig.
Odds Ratio
0
5
10
15
Odds Ratio

193

194 **FIGURE LEGEND**

195

196 **Figure 1**: **A) Statistical power compared to sample size** Assuming 2:1 allocation, a study would
197 need 186 subjects (124 vs. 62) to have 80% statistical power to detect a difference in seizure
198 freedom of 66.9% in group 1 and 45.5% in group 2 (odds ratio 2.4). However, the median SEEG
199 study has only around 24% power to detect this difference. **B) Statistical power compared to**
200 **chance study is false.** Assuming a pre-test probability of 50% that the alternative hypothesis is true
201 and a statistical test with alpha = 0.05, the chance a study with 80% statistical power which a
202 significant result is false is 5.9%. However, the median EEG study with 24% statistical power with a
203 significant result has a 17% chance of being false. **C) Median odds ratio for significant versus**
204 **non-significant results.** We defined a "typical" SEEG study as having the median sample size (38)
205 with the median allocation percentage (63%), which rounded to 24 subjects in group 1 and 14 in
206 group 2. When this experiment is simulated, the median odds ratio that is significant at $p<0.05$ is 5.4,
207 which is more than double the true odds ratio of 2.4. Thus a typical underpowered study, if it finds
208 an significant result, will overestimate the effect size.

REFERENCES

209

210 1. Cohen J. The statistical power of abnormal-social psychological research: A review The
211 Journal of Abnormal and Social Psychology. 1962 1962/09//;65:145-153.
212 2. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure:
213 why small sample size undermines the reliability of neuroscience Nat Rev Neurosci. 2013
214 May;14:365-376.
215 3. Ioannidis JPA. Why Most Published Research Findings Are False PLoS Med. 2005
216 2005/08/30/;2:e124.
217 4. Ioannidis JPA. Why Most Discovered True Associations Are Inflated Epidemiology. 2008
218 2008/09//;19:640-648.
219 5. Dickey AS, Pedersen NP. Low statistical power in a study predicting seizure outcome
220 Epilepsia. 2021 Oct;62:2565-2566.
221 6. Cardinale F, Rizzi M, Vignati E, Cossu M, Castana L, d'Orio P, et al.
222 Stereoelectroencephalography: retrospective analysis of 742 procedures in a single centre Brain.
223 2019 Sep 1;142:2688-2704.
224 7. Moulos P. Chi-square test - contingency tables Available at:
225 https://www.mathworks.com/matlabcentral/fileexchange/18705-chi-square-test-contingency-tables.
226 Accessed November 30.
227 8. Wang H, Chow S-C. Sample Size Calculation for Comparing Proportions. Wiley
228 Encyclopedia of Clinical Trials 2007. p. 1-11.
229 9. Collins MW, Morris SB. Testing for adverse impact when sample size is small Journal of
230 Applied Psychology. 2008 2008;93:463.

231 10. Biau DJ, Jolles BM, Porcher R. P Value and the Theory of Hypothesis Testing: An
232 Explanation for New Researchers Clinical Orthopaedics & Related Research. 2010
233 2010/03//;468:885-892.
234 11. Wasserstein RL, Lazar NA. The ASA Statement on p -Values: Context, Process, and
235 Purpose The American Statistician. 2016 2016/04/02/;70:129-133.
236 12. Trebuchon A, Racila R, Cardinale F, Lagarde S, McGonigal A, Lo Russo G, et al. Electrical
237 stimulation for seizure induction during SEEG exploration: a useful predictor of postoperative
238 seizure recurrence? J Neurol Neurosurg Psychiatry. 2020 Oct 28.
239 13. Dickey AS, Krafty RT, Pedersen NP. Ordinal regression increases statistical power to predict
240 epilepsy surgical outcomes. preprint. Neurology, 2021 2021/10/04/. Report No.
241 14. Cossu M, Cardinale F, Castana L, Citterio A, Francione S, Tassi L, et al.
242 Stereoelectroencephalography in the Presurgical Evaluation of Focal Epilepsy: A Retrospective
243 Analysis of 215 Procedures Neurosurgery. 2005;57:706-718.
244 15. Grewal SS, Alvi MA, Perkins WJ, Cascino GD, Britton JW, Burkholder DB, et al.
245 Reassessing the impact of intraoperative electrocorticography on postoperative outcome of patients
246 undergoing standard temporal lobectomy for MRI-negative temporal lobe epilepsy J Neurosurg.
247 2019 Feb 22;132:605-614.
248 16. Lagarde S, Buzori S, Trebuchon A, Carron R, Scavarda D, Milh M, et al. The repertoire of
249 seizure onset patterns in human focal epilepsies: Determinants and prognostic values Epilepsia. 2019
250 Jan;60:85-95.
251 17. Bourdillon P, Isnard J, Catenoix H, Montavont A, Rheims S, Ryvlin P, et al. Stereo
252 electroencephalography-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) in drug-
253 resistant focal epilepsy: Results from a 10-year experience Epilepsia. 2017 Jan;58:85-93.

254 18. Tassi L, Garbelli R, Colombo N, Bramerio M, Russo GL, Mai R, et al. Electroclinical, MRI
255 and surgical outcomes in 100 epileptic patients with type II FCD Epileptic Disord. 2012 Sep;14:257-
256 266.

257

TABLE

Author	Year	Ntot	N1	N2	Power	(+) Finding	Outcome	SR (+)	SR (-)
Cardinale[6]	2019	470	305	165	99%	MRI lesion	Engel I	67%	45%
Trebuchon[12]	2020	346	120	226	97%	Seizure induced with LFS	Engel I	72%	59%
Cossu[14]	2005	165	123	42	70%	MRI lesion	Engel I	63%	38%
Grewal[15]	2019	127	75	46	65%	Full ECOG field resection	Excellent	65%	52%
Lagarde[16]	2018	143	114	29	57%	Low-voltage fast activity	Engel I	60%	31%
Bourdillon[17]	2017	91	44	47	56%	Favorable initial RF-TC	Good	93%	55%
Tassi[18]	2012	100	66	34	55%	Balloon cell histology	Engel I	88%	74%

258

259 **Table 1: Selected SEEG studies with greater than 50% statistical power.** Power was calculated
260 assuming to detect a difference in seizure freedom of 66.9% in group 1 and 45.5% in group 2 (Odds
261 Ratio 2.4). Only 7/69 (10%) of studies have more than 50% power. Column titles report the first
262 author (Author), year of publication (Year), total sample size (Ntot) and size of the positive (N1) and
263 negative group (N2), the estimated power (Power), the finding present in the positive group (+
264 Finding), surgical outcome (Outcome), and the percentage of patients with seizure reduction in the
265 positive (SR+) or negative group (SR-). Abbreviations: MRI magnetic resonance imaging, LFS low
266 frequency stimulation, ECOG electrocorticography, RF-TC radiofrequency thermocoagulation.

267

268

269

270

271

272

Appendix S1: Raw patient counts from 69 studies. For left to right, columns list the paper ID (#), the first author (First Author), year of publication (Year), journal of publication, (Journal), the total sample size (nTot) and the size of the positive (N1) and negative (N2) prognostic groups.

#	First_Author	Year	Journal	nTot	N1	N2
1	Brekelmans	1998	Epilepsia	44	34	10
2	Chassoux	2000	Brain	27	22	5
3	Trinka	2000	Epileptic Disord	24	8	16
4	Cossu	2005	Neursurgery	165	123	42
5	Cossu	2005	J Neurosurg	35	29	6
6	Sindou	2006	Acta Neurochir	100	87	13
7	McGonigal	2007	Brain	60	40	20
8	Rheims	2008	Epilepsy Research	15	10	5
9	Devaux	2008	Neurochirurgie	74	64	10
10	Catenoix	2008	Neurology	41	21	20
11	Aubert	2009	Brian	28	8	21
12	Chassoux	2010	Neurology	23	10	13
13	Regis	2011	Neurosurgery	12	8	4
14	Chassoux	2012	Epilepsia	62	25	37
15	Liava	2012	Epilepsy and Behavior	53	39	13
16	Tassi	2012	Epileptic Disord	100	66	34
17	Wasade	2013	Brit Jour of Neurosurg	16	10	6
18	Gonzalez-Martinez	2013	Epilepsia	53	28	25
19	Jung	2013	Brain	11	7	4
20	Antony	2013	Plos One	23	11	12
21	Chassoux	2012	Neurology	37	33	4
22	Liava	2014	Epileptic Disord	62	45	17
23	Taussig	2014	Epileptic Disord	51	19	32
24	Catenoix	2015	Neurosurgery	16	8	8
25	Cossu	2015	J Neurosurg	89	14	75
26	Gonzelez-Martinez	2016	Neurosurgery	68	37	31
27	Barba	2016	Brain	168	150	18
28	Lagarde	2016	Epilepsia	53	44	9
29	Murakami	2016	Brain	50	26	24
30	Bourdillon	2017	Epilepsia	91	44	47
31	Dimova	2017	Epilepsia	23	8	15
32	Kubota	2017	Clin Neuro and Neurosurg	11	4	7
33	Bonini	2017	Neurosurgery	38	24	14
34	Wang	2017	NeuroImage: Clinical	43	27	16

35	Mirandola	2017	Epilepsia	20	16	4
36	Roessler	2017	World Neurosurgery	24	11	13
37	Youngerman	2018	Epilepsia	30	18	12
38	Vaugier	2018	Epilepsy and Behavior	12	8	4
39	Nagahama	2018	J Neurosurg	33	29	4
40	Lagarde	2018	Epilepsia	143	114	29
41	McGovern	2018	J Neurosurg Pediatr	42	21	21
42	Steriade	2019	Epilepsia	75	61	14
43	Thorsteinsdottir	2019	Journal of Neurology	70	42	28
44	Grewal	2019	J Neurosurg	127	75	46
45	Tandon	2019	JAMA Neurology	57	36	39
46	Popescu	2019	J Neuroimaging	16	5	11
47	Rizzi	2019	J Neurosurg	42	36	6
48	Lagarde	2019	Journal of Neurology	59	42	17
49	Mariani	2019	Journal of Neurology	46	28	18
50	Mullati	2019	Epilepsia	14	9	5
51	Liu	2019	Int J of Neuroscience	47	37	10
52	Cardinale	2019	Brain	470	305	165
53	Duhrsen	2020	Neurosurgical Review	18	8	10
54	Peedicail	2020	Acta Neurol Scand	23	11	12
55	Kappen	2020	Seizure: Eur J of Epilepsy	8	5	3
56	Mohamed	2020	Neurosurg Focus	41	23	18
57	Gao	2020	Epilepsy Research	19	10	9
58	Steriade	2020	Clinical Neurophysiology	16	9	7
59	Qi	2020	Frontiers in Human Neuro	19	17	2
60	Feng	2020	Clinical Neurophysiology	25	13	12
61	Lesko	2020	J Neurosurg Pediatr	54	37	17
62	Gupta	2020	Epilepsia	32	16	16
63	Zhao	2020	J Neurosurg	25	14	11
64	Fierain	2020	Epilepsy and Behavior	12	7	5
65	Yuan	2020	Seizure: Eur J of Epilepsy	31	23	8
66	Zhang	2020	Seizure: Eur J of Epilepsy	42	27	15
67	Trebuchon	2020	J Neurol Neurosurg Psych	346	120	226
68	Zaher	2020	Frontiers in Neurology	9	4	5
69	Yan	2020	Chinese Medical Journal	30	18	12

276